Innovative Technology Autonomous Therapeutics utilizes a groundbreaking class of nucleic acids, Encrypted RNATM, which offers precision and variant-proof protection against diverse diseases, presenting a unique opportunity for partners interested in next-generation immunotherapy solutions.
Growing Market Focus With recent news emphasizing artificial immune systems that are inhalable and variant-proof, the company is positioned at the forefront of pandemic and cancer-related treatments, ideal for collaborations with biotech firms aiming to expand into advanced immuno-oncology and infectious disease markets.
Financial Range The company's revenue estimate of 10 to 25 million dollars suggests it is an emerging player with potentially scalable solutions, making it an attractive target for strategic partnerships, licensing, or investment to accelerate development and commercialization efforts.
Research Excellence Founded by inventors from Harvard Medical School and UCSF, Autonomous Therapeutics benefits from a strong scientific foundation, providing confidence in its innovative pipeline and opening opportunities for collaboration with academic and research institutions.
Market Differentiation By developing inhalable and variant-proof immune systems using proprietary RNA technology, the company differentiates itself in biotech, creating opportunities to engage with pharmaceutical and biotech companies seeking disruptive therapies in infectious and chronic diseases.
$25M$50M
$1B$10B
$10M$25M
$50M$100M
$250M$500M
$100M$250MAutonomous Therapeutics uses 8 technology products and services including Squarespace, Open Graph, Google Fonts API, and more. Explore Autonomous Therapeutics's tech stack below.
| Autonomous Therapeutics Email Formats | Percentage |
| First@autonomous.bio | 64% |
| First.Last@autonomous.bio | 25% |
| FirstLast@autonomous.bio | 5% |
| Last@autonomous.bio | 6% |
Biotechnology ResearchUnited States11-50 Employees
Autonomous Therapeutics is a synthetic immunology company founded by inventors from Harvard Medical School and UCSF. We are developing next-generation precision medicines using a new class of nucleic acids. Encrypted RNA™ enables precision and variant-proof protection from pandemic influenza to metastatic cancers. Reach out if you want to join us!
Company Overview
Funding & FinancialsAutonomous Therapeutics's revenue is estimated to be in the range of $10M$25M
Funding & FinancialsAutonomous Therapeutics's revenue is estimated to be in the range of $10M$25M
1-888-653-2347 
support@leadiq.com